🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BioCryst Pharmaceuticals, Inc. BCRX R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.biocryst.com
Company Profile ↓
$9.74
+8.71% 1Y
Mkt Cap$2.48B
P/E-5.50
P/B-3.99
52W High$11.11
52W Low$6.24
Book Value$-2.18
EPS (TTM)$-1.77

Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 107.2%.

Steady Revenue Expansion

Revenue has grown at a 16.6% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $874.84M (+94.1% YoY); net profit $263.86M.
  • Trailing 12 Months Year-on-year growth — revenue +7.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.63%
1 Year:7.50%

Stock Price Performance

1 Year:+8.71%
6 Months:+31.62%
3 Months:+3.51%
1 Month:+14.59%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 72% of range
$6.24 $11.11
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.57 · Neutral
Price Performance
1M+14.59%
3M+3.51%
6M+31.62%
1Y+8.71%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 107.2%.
  • Compounding revenue at 16.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-5.50
Industry PE
25.41
Forward P/E
14.32
PEG Ratio
9.39
Book Value
$-2.18
Price to Book
-3.99
P/S
2.50
EV/EBITDA
8.67
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
16.63%
Profit 5Y
-
Revenue (YoY)
7.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
107.20%
ROE
-
ROA
42.62%
Profit Margin
-51.71%
Op Margin
-2.45%
Gross Margin
76.63%
EPS (Latest Qtr)
$-2.98
EPS (TTM)
$-1.77

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
1.78
Current Ratio
1.91
Debt
$858.08M
Total Assets
$465.05M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.20%
Chg in Prom Hold
0.06%
FII / Inst Holding
101.13%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$2.48B
Total Revenue (TTM)
$885.72M
EBITDA
$326.46M
Free Cash Flow
$264.38M
Operating Cash Flow
$313.10M
Shares Outstanding
254.16M
Gross Margin
76.63%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BCRX BioCryst Pharmaceuticals, Inc. R2K 9.74 -5.50 $2.48B 0.00% 107.20% - 16.63% -
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 6.83M25.84M10.99M-4.82M4.79M7.76M-9.44M3.10M8.76M-----------------------------
Operating Income -14.43M5.34M-13.16M--19.05M-12.13M-9.24M--10.69M-15.52M-13.35M--22.21M-18.25M-28.49M--29.33M-34.92M-35.10M--40.98M-38.51M-42.86M--51.38M-29.58M-44.58M-49.96M-34.72M-17.45M-28.41M-20.70M-11.92M-14.49M8.76M7.69M21.23M29.79M29.59M-701.60M
Net Income -15.16M4.90M-14.62M-18.14M-22.83M-16.28M-11.53M-4.50M-14.22M-16.89M-15.13M-19.54M-25.78M-18.45M-29.60M-27.43M-31.05M-37.63M-37.59M-2.62M-37.60M-38.61M-46.12M-60.49M-64.28M-43.20M-58.80M-74.20M-58.86M-42.52M-53.33M-75.33M-36.15M-35.38M-12.67M-14.03M32.00K5.08M12.90M-721.81M
Diluted EPS -0.210.06-0.20-0.25--0.22--------------------0.24-0.33-0.40-0.32-0.23-0.28-0.40-0.19-0.17-0.06-0.070.000.020.06-2.98
R&D Expense 17.12M16.52M20.07M-20.58M14.17M14.11M-16.77M15.76M17.51M-18.44M21.01M22.01M-27.49M27.68M25.12M-29.87M27.50M30.25M-42.44M52.87M49.97M65.36M61.99M52.74M48.39M51.25M46.88M46.49M37.62M41.08M37.27M43.39M44.60M60.32M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 74.59M62.38M19.64M26.29M17.33M13.61M48.26M26.35M25.19M20.65M48.84M17.81M157.17M270.83M331.41M450.71M874.84M
Operating Income -13.74M-34.36M-49.59M-33.89M-30.72M-45.77M-39.44M-48.61M-57.41M-94.22M-99.45M-174.76M-177.72M-148.44M-103.71M-2.54M340.99M
Net Income -13.45M-33.85M-56.95M-39.08M-30.11M-45.19M-43.02M-55.14M-65.78M-101.25M-108.90M-182.81M-184.06M-247.12M-226.54M-88.88M263.86M
Diluted EPS ------------1.09-1.03-1.33-1.18-0.431.21
R&D Expense 73.66M83.90M57.25M49.16M41.94M51.80M72.76M61.01M66.96M84.89M107.07M122.96M208.81M253.30M216.57M174.64M166.13M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --109.45M82.21M57.44M48.87M136.87M122.36M89.85M178.26M146.84M175.28M334.71M588.15M550.00M516.96M490.42M514.16M
Total Equity 46.43M86.27M65.50M14.81M-454.00K-1.13M75.64M47.72M1.58M83.77M49.23M38.25M-19.26M-106.99M-294.60M-455.53M-475.93M-119.15M
Cash & Equivalents 22.34M41.12M13.62M16.44M20.89M21.16M54.54M28.90M22.10M50.28M26.73M114.17M272.13M504.39M304.77M110.64M104.71M89.74M
Long Term Debt --------23.00M23.00M30.00M0119.73M136.08M231.62M303.23M314.87M0
Total Liabilities ---------------972.49M966.35M633.31M
Current Liabilities --28.00M26.30M17.22M15.26M57.29M62.26M54.36M74.84M69.48M92.33M105.65M103.72M105.51M149.99M160.38M196.07M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -16.22M-28.55M-32.25M-37.40M-26.53M-13.12M-53.44M-41.14M-92.56M-89.58M-135.11M-142.16M-161.85M-95.14M-52.02M347.37M
Investing Cash Flow -12.89M221.00K11.32M24.88M-3.47M-18.00M23.27M-64.64M4.77M77.93M-6.86M15.80M-128.24M-131.50M52.59M-13.69M
Financing Cash Flow 47.90M831.00K23.75M16.96M30.27M5.48M23.30M135.70M62.50M99.10M300.59M359.67M88.03M32.48M-5.76M-349.93M
Capital Expenditure --------328.00K-366.00K-343.00K------
Free Cash Flow --------41.47M-92.93M-89.93M------
Share Buybacks 155.00K5.00K61.00K-------------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % -18.4%-55.1%-252.4%-128.9%-177.2%-336.4%-81.7%-184.4%-227.9%-456.2%-203.7%-981.1%-113.1%-54.8%-31.3%-0.6%39.0%
Net Margin % -18.0%-54.3%-289.9%-148.6%-173.7%-332.1%-89.1%-209.3%-261.2%-490.3%-223.0%-1,026.4%-117.1%-91.2%-68.4%-19.7%30.2%
ROE % -15.6%-51.7%-384.6%8,608.1%2,673.9%-59.7%-90.1%-3,494.6%-78.5%-205.7%-284.7%949.1%172.0%83.9%49.7%18.7%-221.4%
ROCE % --42.2%-88.7%-84.3%-91.4%-57.5%-65.6%-137.0%-55.5%-121.8%-119.9%-76.3%-36.7%-33.4%-28.3%-0.8%107.2%

Shareholding Pattern

Insiders
1.20%
Institutions
101.13%
Public Float
102.36%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.91% 22.65M $224.24M
2 RA Capital Management, L.P. 6.23% 15.83M $156.69M
3 Deerfield Management Company, L.P 5.92% 15.04M $148.88M
4 State Street Corporation 4.80% 12.21M $120.86M
5 Vanguard Portfolio Management LLC 4.42% 11.24M $111.32M
6 Vanguard Capital Management LLC 4.38% 11.14M $110.24M
7 TCG Crossover Management, LLC 4.34% 11.02M $109.11M
8 Janus Henderson Group PLC 3.51% 8.91M $88.19M
9 Perceptive Advisors Llc 2.92% 7.43M $73.60M
10 Vestal Point Capital, LP 2.76% 7.03M $69.55M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BCRX

Yahoo Finance ue, 14 Jul 2026

Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock wil…

Yahoo Finance hu, 09 Jul 2026

BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers

BioCryst Pharmaceuticals stock has delivered a 54.7% return over the past three years, and the latest valuation checks still suggest the shares lean cheap rather than stretched. A 54.7% three year return puts BioCryst in clear recovery terr…

Yahoo Finance hu, 09 Jul 2026

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.

Yahoo Finance hu, 09 Jul 2026

BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility

BioCryst Pharmaceuticals (NasdaqGS:BCRX) is ending its internal discovery programs and closing its Birmingham, Alabama facility. The company plans to pivot toward external innovation in rare diseases, focusing on partnered or acquired asset…

Yahoo Finance Wed, 08 Jul 2026

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo Finance Wed, 08 Jul 2026

VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

BCRX — Frequently Asked Questions

What is the current share price of BioCryst Pharmaceuticals, Inc. (BCRX)?

As of 2026-07-14 21:23 PDT, BioCryst Pharmaceuticals, Inc. (BCRX) trades at $9.74 on NasdaqGS. Its 52-week range is $6.24 to $11.11.

What is the market capitalisation of BCRX?

BioCryst Pharmaceuticals, Inc. (BCRX) has a market capitalisation of $2.48B on NasdaqGS.

What is the P/E ratio of BCRX?

BCRX trades at a trailing price-to-earnings (P/E) ratio of -5.50. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -3.99.

Is BCRX a good stock to buy?

This page provides a data-driven analysis of BioCryst Pharmaceuticals, Inc. (BCRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space